Canakinumab Cuts Secondary CV Events in Phase 3 CANTOS

11:20 EDT 22 Jun 2017 | Medscape

Top-line results show the monoclonal antibody, given on top of standard care, significantly reduced the risk of cardiovascular death, nonfatal MI, and nonfatal stroke in patients with a prior MI and elevated CRP.
Medscape Medical News

Original Article: Canakinumab Cuts Secondary CV Events in Phase 3 CANTOS


More From BioPortfolio on "Canakinumab Cuts Secondary CV Events in Phase 3 CANTOS"

Quick Search


Relevant Topics

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...